EZH2 and cancer: In fact, the overexpression of EZH2 has been shown to be associated with invasive growth and poor clinical outcomes in many malignant tumors, including breast, prostate, gastric, endometrial and hematologic cancers, even though the prognostic impact of H3K27me3 expression is variable (25–29).